|Awarded On||November 19, 2015|
|Title||Radiogenomic Screen to Identify Novel Proliferation-associated Glioblastoma Genomic Therapeutic Targets: Discovery and Mechanistic Validation Study|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Rivka R Colen|
|Cancer Sites||Brain and Other Nervous System|
The purpose of the research is to uncover and validate novel, relevant, and clinically meaningful genomic targets that can be subsequently developed into a therapeutic and more personalized treatment for Glioblastoma, the most common primary brain tumor. Currently, the absence of a validated method for early and cost-effective genomic target identification and selection remains a critical barrier to the development of targeted therapeutics and personalized medicine; thus, despite recent advances in novel sequencing and microarray technologies, little progress has been made and the clinical course and everyday life of a cancer patient remains largely unchanged. This study is needed to address...